The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose Tissue
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02038595 |
Recruitment Status :
Completed
First Posted : January 16, 2014
Last Update Posted : March 30, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Brown Adipose Tissue | Radiation: PET imaging | Early Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose Tissue |
Study Start Date : | September 2012 |
Actual Primary Completion Date : | December 2013 |
Actual Study Completion Date : | December 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Healthy subjects
Healthy subjects (male, female)
|
Radiation: PET imaging |
- detection of brown adipose tissue based on PET imaging [ Time Frame: 1 year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 30 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- age 18-30 yrs
- BMI < 24 kg/m2
- Caucasian
Exclusion Criteria:
- Current neuro-psychiatric illness
- substance abuse
- medical or neurological illnesses likely to affect physiology or anatomy, i.e., uncontrolled hypertension, cardiovascular disorders
- current pregnancy
- current breast feeding
- suicidal ideation or behavior
- use of medications which potentially affect NET binding within 2 weeks of the PET scans.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02038595
United States, Connecticut | |
Yale University | |
New Haven, Connecticut, United States, 06510 |
Principal Investigator: | Robert Sherwin, MD | Yale University |
Responsible Party: | Yale University |
ClinicalTrials.gov Identifier: | NCT02038595 |
Other Study ID Numbers: |
1008007284 |
First Posted: | January 16, 2014 Key Record Dates |
Last Update Posted: | March 30, 2020 |
Last Verified: | July 2015 |
brown adipose tissue |